H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the 11 Best Stocks to Buy for Investment. On January 9, H.C. Wainwright reiterated a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO), maintaining the price target at $90. Mitchell Kapoor from H.C. Wainwright remains positive on HALO, considering the strategic and financial strength of its ENHANZE platform. Kapoor believes the recent business developments with Takeda and Skye are a significant win for the company, expanding ENHANZE’s reach beyond ...